Cargando…

Spike Antibody Titers Evaluation after a 2-Dose Regimen of BNT162b2 Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2

Detalles Bibliográficos
Autores principales:	Kayukawa, Satoshi, Nanya, Kengo, Morita, Makoto, Ina, Kenji, Ota, Yoshihiro, Hasegawa, Shinji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579918/ https://www.ncbi.nlm.nih.gov/pubmed/34756062 http://dx.doi.org/10.1128/Spectrum.01036-21

Ejemplares similares

Long-Term Neutralizing Antibody Titers After BNT162b2 Vaccination in Hemodialysis Patients
por: Takazono, Takahiro, et al.
Publicado: (2023)

Serological response 5 months after the BNT162b2 COVID-19 vaccination in patients with various hematological disorders in Japan
por: Marumo, Yoshiaki, et al.
Publicado: (2023)

Inhaled corticosteroids do not affect the antibody titer against the SARS-CoV-2 spike protein in BNT162b2 mRNA vaccinated patients
por: Nakajima, Takeo, et al.
Publicado: (2022)

Association between γ-Glutamyl Transpeptidase and SARS-CoV-2 Spike Antibody Titers among BNT162b2 Vaccine Recipients
por: Islam, Zobida, et al.
Publicado: (2022)

Sex‐associated differences between BMI and SARS‐CoV‐2 antibody titers following the BNT162b2 vaccine
por: Yamamoto, Shohei, et al.
Publicado: (2022)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Blood Antibody Titers and Adverse Reactions after BNT162b2 mRNA Vaccination
por: Kiewisz, Jolanta, et al.
Publicado: (2022)

Neutralizing antibody titers to Omicron six months after vaccination with BNT162b2 in Colombia
por: Zapata-Cardona, María I., et al.
Publicado: (2022)

Effect of the third dose of BNT162b2 vaccine on quantitative SARS-CoV-2 spike 1–2 IgG antibody titers in healthcare personnel
por: Romero-Ibarguengoitia, Maria Elena, et al.
Publicado: (2022)

Associations of HLA Polymorphisms with Anti-SARS-CoV-2 Spike and Neutralizing Antibody Titers in Japanese Rheumatoid Arthritis Patients Vaccinated with BNT162b2
por: Higuchi, Takashi, et al.
Publicado: (2023)

Underlying medical conditions and anti-SARS-CoV-2 spike IgG antibody titers after two doses of BNT162b2 vaccination: A cross-sectional study
por: Li, Jiaqi, et al.
Publicado: (2023)

SARS-CoV-2 anti-spike antibody titres after vaccination with BNT162b2 in naïve and previously infected individuals
por: Lombardi, Andrea, et al.
Publicado: (2021)

Erythema Multiforme after BNT162b2 Vaccination
por: Katayama, Sho, et al.
Publicado: (2022)

A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen
por: Baek, Yae Jee, et al.
Publicado: (2023)

Peak IgG antibody titers against SARS-CoV-2 spike protein following immunization with the Pfizer/BioNTech BNT162b2 vaccine
por: Kobashi, Yurie, et al.
Publicado: (2022)

Antibody titers against SARS-CoV-2 spike protein 6 months after a third BNT162b2 vaccine in chronic hemodialysis patients
por: El Haggan, Wael, et al.
Publicado: (2022)

BNT162b2 SARS-CoV-2 Vaccination Elicits High Titers of Neutralizing Antibodies to Both B.1 and P.1 Variants in Previously Infected and Uninfected Subjects
por: Vicenti, Ilaria, et al.
Publicado: (2021)

Rapidly Declining SARS-CoV-2 Antibody Titers within 4 Months after BNT162b2 Vaccination
por: Jo, Dong-Ho, et al.
Publicado: (2021)

Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine
por: Ferrari, Davide, et al.
Publicado: (2021)

One-year dynamics of antibody titers after three doses of SARS-CoV-2 BNT162b2 vaccine
por: Wand, Ori, et al.
Publicado: (2023)

Delayed urticaria after BNT162b2 booster vaccination at previous intradermal test site with severe acute respiratory syndrome-coronavirus-2 spike protein
por: Triwatcharikorn, Jidapa, et al.
Publicado: (2022)

Antibody titers among healthcare workers for coronavirus disease 2019 at 6 months after BNT162b2 vaccination
por: Kurashima, Kazuyoshi, et al.
Publicado: (2022)

BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants
por: Liu, Yang, et al.
Publicado: (2021)

Effect of Heterologous Vaccination Regimen with Ad5-nCoV CanSinoBio and BNT162b2 Pfizer in SARS-CoV-2 IgG Antibodies Titers †
por: Romero-Ibarguengoitia, Maria Elena, et al.
Publicado: (2022)

Short-Term Drop in Antibody Titer after the Third Dose of SARS-CoV-2 BNT162b2 Vaccine in Adults
por: Herzberg, Jonas, et al.
Publicado: (2022)

Antibody Titers After a Third and Fourth SARS-CoV-2 BNT162b2 Vaccine Dose in Older Adults
por: Eliakim-Raz, Noa, et al.
Publicado: (2022)

Factors associated with anti-SARS-CoV-2 spike antibody titers after a second BNT162b2 mRNA COVID-19 vaccination in Japanese hemodialysis patients
por: Hirai, Keiji, et al.
Publicado: (2022)

The clinical course of patients with previous acute and recurrent pericarditis receiving the BNT162b2 vaccine
por: Wasserstrum, Yishay, et al.
Publicado: (2022)

Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals
por: Manisty, Charlotte, et al.
Publicado: (2021)

Immune Assessment of BNT162b2 m-RNA-Spike Based Vaccine Response in Adults
por: San Segundo, David, et al.
Publicado: (2021)

Association of Impaired Fasting Glucose and Diabetes with SARS-CoV-2 Spike Antibody Titers after the BNT162b2 Vaccine among Health Care Workers in a Tertiary Hospital in Japan
por: Islam, Zobida, et al.
Publicado: (2022)

Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection
por: Israel, Ariel, et al.
Publicado: (2021)

Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection
por: Israel, Ariel, et al.
Publicado: (2021)

Low Neutralizing Antibody Titers against the Mu Variant of SARS-CoV-2 in 31 BNT162b2 Vaccinated Individuals in Colombia
por: Álvarez-Díaz, Diego A., et al.
Publicado: (2022)

Side effects and antibody titer transition of the BNT162b2 messenger ribonucleic acid coronavirus disease 2019 vaccine in Japan
por: Izumo, Takehiro, et al.
Publicado: (2021)

Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru
por: Vargas-Herrera, Natalia, et al.
Publicado: (2022)

Increased Mild Vaccine-Related Side Effects and Higher Specific Antibody Titers in Health Care Workers with Previous SARS-CoV-2 Infection after the mRNA BNT162b2 Vaccine
por: Ferrari, Ludovica, et al.
Publicado: (2022)

Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
por: Ebinger, Joseph E., et al.
Publicado: (2021)

Neutralizing Antibodies Titers and Side Effects in Response to BNT162b2 Vaccine in Healthcare Workers with and without Prior SARS-CoV-2 Infection
por: Morales-Núñez, José Javier, et al.
Publicado: (2021)

Spike-antibody waning after second dose of BNT162b2 or ChAdOx1
por: Shrotri, Madhumita, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hik9uk8dfr86b7mef9s1f04v75